iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect iTeos Therapeutics to post earnings of ($0.94) per share and revenue of $1.80 million for the quarter.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. On average, analysts expect iTeos Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
iTeos Therapeutics Price Performance
iTeos Therapeutics stock opened at $7.50 on Friday. The stock's fifty day moving average is $6.57 and its two-hundred day moving average is $7.55. The stock has a market cap of $286.46 million, a PE ratio of -2.38 and a beta of 1.43. iTeos Therapeutics has a 1-year low of $4.80 and a 1-year high of $18.75.
Wall Street Analyst Weigh In
ITOS has been the topic of several research reports. Wells Fargo & Company dropped their price objective on iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating on the stock in a report on Tuesday. Wedbush reissued an "outperform" rating and set a $25.00 price target on shares of iTeos Therapeutics in a report on Wednesday, March 5th. HC Wainwright reaffirmed a "buy" rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Thursday, March 6th. Finally, JPMorgan Chase & Co. cut their price target on iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, March 6th.
Get Our Latest Analysis on iTeos Therapeutics
iTeos Therapeutics Company Profile
(
Get Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
